Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by Verition Fund Management LLC

Verition Fund Management LLC lowered its position in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 63.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,642 shares of the biopharmaceutical company’s stock after selling 21,694 shares during the quarter. Verition Fund Management LLC’s holdings in Theravance Biopharma were worth $102,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Los Angeles Capital Management LLC acquired a new stake in shares of Theravance Biopharma in the 2nd quarter worth approximately $286,000. American Century Companies Inc. boosted its position in Theravance Biopharma by 11.7% during the second quarter. American Century Companies Inc. now owns 57,611 shares of the biopharmaceutical company’s stock worth $489,000 after purchasing an additional 6,026 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Theravance Biopharma by 38.4% in the second quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock valued at $2,800,000 after purchasing an additional 91,679 shares during the last quarter. Hsbc Holdings PLC acquired a new position in shares of Theravance Biopharma during the 2nd quarter worth $108,000. Finally, XTX Topco Ltd purchased a new stake in shares of Theravance Biopharma in the 2nd quarter worth about $129,000. 99.10% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Theravance Biopharma in a report on Monday, September 16th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $13.75.

Theravance Biopharma Price Performance

Theravance Biopharma stock opened at $9.80 on Tuesday. Theravance Biopharma, Inc. has a fifty-two week low of $7.44 and a fifty-two week high of $11.71. The firm’s 50 day simple moving average is $9.08 and its 200-day simple moving average is $8.78. The company has a market cap of $481.91 million, a P/E ratio of -9.70 and a beta of 0.23.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The business had revenue of $16.87 million during the quarter, compared to analyst estimates of $16.11 million. During the same period in the previous year, the firm posted ($0.17) EPS. On average, analysts expect that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now directly owns 322,743 shares in the company, valued at approximately $2,904,687. This trade represents a 1.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.